The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Apax opts against lifting offer; DCI enters loan deal

Fri, 09th Feb 2024 18:53

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

----------

RTW Biotech Opportunities Ltd - New York-based investment firm focused on the life sciences sector - Notes announcement by Kyverna Therapeutics regarding its pricing of a USD319 million initial public offering, upsized USD137 million above its initial estimate last week. Kyverna is a clinical-stage cell therapy biopharma company, in which RTW initially invested through a Series B funding round in early 2022. On the first day of trading, Kyverna's share price traded up by 36% to close at USD30.00 per share.

----------

Symphony Environmental Technologies PLC - Hertfordshire-based firm developing technology to make plastic biodegradable - Says that the General Court of the European Union found that the defendants didn't exceed "the limits of their discretion", so Symphony is not entitled to compensation. However, Symphony explains that the judgement was not an assessment of the effectiveness of the d2w technologies. Adds that the court didn't include further studies that have supported the technology, as well as the distinction between oxo-biodegradable and oxo-degradable plastics. Says that d2w technology has not been widely used in the EU for several years, and the lengthy legal process and judgment has "very little effect" on existing business.

----------

Evgen Pharma PLC - clinical stage drug development company developing sulforaphane-based medicines - Notes dispute with Stalicla SA, its partner in autism spectrum disorder and other neurodevelopmental disorders. Explains that in October 2022, Evgen licensed the rights for its lead asset, SFX-01, to Stalicla for up to USD160.5 million in milestone payments. An initial USD500,000 was paid upfront with the next anticipated payment of USD500,000 due on completion of the Evgen-sponsored human volunteer Phase 1 study. Evgen, having completed a Phase 1b study, believes the next payment is now due, and says it has formally implemented the dispute resolution process. It had not anticipated any milestone payments from Stalicla in its financial forecasting, and its cash runway remains unchanged.

----------

Substrate Artificial Inteligence SA - Madrid-based incubator of companies providing artificial intelligence products and services in fintech, agritech, energy, human resources, and health sectors - Signs investment deal with Indico Investments and Management SL, for a maximum of EUR2.0 million. The investment commitment, which expires on February 7, relates to the company's Class A shares. It will be carried out in tranches of EUR500,000, with a discount of 10%.

----------

DCI Advisors Ltd - British Virgin Islands-based real estate investment company - Says it has entered another loan agreement for EUR350,000 with a shareholder to provide additional working capital. The shareholder providing this loan previously entered into a loan agreement with DCI Advisors for EUR350,000 last October. To date, DCI has received seven loans of EUR350,000 each and two loans from funds managed by a single shareholder amounting to USD330,000 in aggregate.

----------

Apax Global Alpha Ltd - Guernsey-based investor in technology, services, healthcare, internet and consumer - Confirms that the offer of 120 pence in cash per Kin and Carta PLC share is final and will not be increased. In December, Apax said that a 'no increase statement' relating to its own offer price was no longer in effect and had been set aside, after Kin & Carta accepted an offer of 130p per share from Valtech, a company controlled by funds advised by London-based BC Partners LLP.

----------

Sutton Harbour Group PLC - Plymouth, England-based waterfront regeneration specialist - Notes press statement made by Plymouth City Council on Thursday, and confirms that it has received a letter from the Council alleging a breach of the Plymouth City Airport lease. Says that it is considering, in conjunction with its advisers, the contents of the letter, and will provide an update in due course.

----------

By Holly Beveridge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
23 Nov 2020 17:37

IN BRIEF: Evgen Pharma Doses First Patient In Lead Candidate Trial

IN BRIEF: Evgen Pharma Doses First Patient In Lead Candidate Trial

Read more
23 Nov 2020 12:22

Evgen doses first patients in 'STAR' respiratory trial

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced on Monday that the first patient had now been enrolled and dosed in the 'STAR' trial of its 'SFX-01' treatment for acute respiratory infections.

Read more
11 Nov 2020 15:53

IN BRIEF: Evgen Pharma About To Begin SFX-01 Trial Recruitment

IN BRIEF: Evgen Pharma About To Begin SFX-01 Trial Recruitment

Read more
23 Oct 2020 11:49

Evgen gets full approval for SFX-01 trial in Covid-19 patients

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced on Friday that all necessary regulatory approvals had now been received for the 'STAR' trial of SFX-01 treatment for Acute Respiratory Infections.

Read more
23 Oct 2020 11:31

Shares In Evgen Pharma Rise On Approval For SFX-01 Trial

Shares In Evgen Pharma Rise On Approval For SFX-01 Trial

Read more
23 Oct 2020 10:46

UK WINNERS & LOSERS SUMMARY: Barclays Lifts FTSE's Lenders

UK WINNERS & LOSERS SUMMARY: Barclays Lifts FTSE's Lenders

Read more
24 Sep 2020 18:12

UK EXECUTIVE CHANGE SUMMARY: Carr's Names Pelham To Replace CEO Davies

UK EXECUTIVE CHANGE SUMMARY: Carr's Names Pelham To Replace CEO Davies

Read more
15 Sep 2020 22:08

UK TRADING UPDATE SUMMARY: Mortgage Advice Bureau Launches Later Life

UK TRADING UPDATE SUMMARY: Mortgage Advice Bureau Launches Later Life

Read more
15 Sep 2020 08:41

Evgen Pharma licences technology to Juvenescence

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced the licensing of its sulforaphane stabilisation technology in a number of non-pharmaceutical applications to Juvenescence on Tuesday.

Read more
9 Jul 2020 16:16

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
17 Jun 2020 12:01

Evgen's 'SFX-01' to be tested with Covid-19 patients

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced its participation in the recently-notified funding initiative for Covid-19 clinical trials by the medical research charity LifeArc on Wednesday.

Read more
17 Jun 2020 10:42

Evgen Pharma Says SFX-01 To Be Evaluated In Covid-19 Trial

Evgen Pharma Says SFX-01 To Be Evaluated In Covid-19 Trial

Read more
15 Jun 2020 11:09

UK WINNERS & LOSERS SUMMARY: Bunzl Rises As It Sees Strong First Half

UK WINNERS & LOSERS SUMMARY: Bunzl Rises As It Sees Strong First Half

Read more
15 Jun 2020 10:24

Evgen Pharma Loss Slightly Wider On Expenses And Compensation

Evgen Pharma Loss Slightly Wider On Expenses And Compensation

Read more
15 Jun 2020 09:51

Losses widen as Evgen Pharma develops SFX-01

(Sharecast News) - Clinical-stage drug development company Evgen Pharma reported a slight widening of its post-tax loss in its final results on Monday, to £2.7m, from £2.6m in the prior year.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.